Clinical trials: Oral Phase
Smoking Cessation
A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation
In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.
- Trial name
- NCT02044874
- Testing
- APD356-lorcaserin hydrochloride
- Where
- 31 sites in United States
- Volunteers
- 603 people
- Sponsor
- Arena Pharmaceuticals
Gingival Recession
Single Stage Root Coverage for Gingival Recession With or Without Free Gingival Graft
Background and Objective: Gingival recession accounts for apical migration of the gingival margin resulting in exposure of the cementoenamel junction (CEJ) and root surface.
- Trial name
- NCT03370042
- Testing
- semilunar coronally positioned flap with free gingival graft, semilunar coronally positioned flap alone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kamineni Institute of Dental Sciences
Sialorrhea Secondary to Parkinson's Disease
Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients
The primary goal of the study is to evaluate the safety and potential efficacy of intra-oral dissolvable NH004 films to improve the short-term symptoms of sialorrhea (drooling) in Parkinson's disease (PD) patients.
- Trial name
- NH004-2 (NCT00761137)
- Testing
- 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
- Where
- Argentina
- Volunteers
- 19 people
- Sponsor
- NeuroHealing Pharmaceuticals Inc.
Solid Tumours
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate renal impairment compared to patients with normal renal function; Part B will allow…
- Trial name
- NCT01894256
- Testing
- Olaparib tablet dosing
- Where
- 13 sites in Belgium, Denmark and 3 more
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Community Acquired Pneumonia
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia
- Trial name
- LEAP2 (NCT02813694)
- Testing
- lefamulin, Moxifloxacin
- Where
- 155 sites in United States, Argentina and 18 more
- Volunteers
- 738 people
- Sponsor
- Nabriva Therapeutics AG
Peanut Allergy
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing…
- Trial name
- NCT03682770
- Testing
- Dupilumab, AR101
- Where
- 25 sites in United States
- Volunteers
- 148 people
- Sponsor
- Regeneron Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or…
- Trial name
- NCT05663866
- Testing
- Dexamethasone, Montelukast, Methotrexate
- Where
- 36 sites in United States, France and 3 more
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small Cell Lung Cancer
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of…
- Trial name
- NCT03974022
- Testing
- Sunvozertinib
- Where
- 124 sites in United States, Argentina and 11 more
- Volunteers
- 315 people
- Sponsor
- Dizal Pharmaceuticals
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Study in Healthy Adults Evaluating PF-07202954
The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).
- Trial name
- NCT04857437
- Testing
- PF-07202954 Repeat Dose, PF-07202954 Single Dose
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2 Infection
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized
The purpose of the study is to understand the effects and safety of PF-07817883 treatment. The study wants to know how PF-07817883 treatment lowers the level of the virus that causes COVID 19.
- Trial name
- NCT05799495
- Testing
- PF-07817883
- Where
- 53 sites in United States
- Volunteers
- 240 people
- Sponsor
- Pfizer
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
This study will take place in parts: Dose Escalation (Part 1): Participants receive milademetan alone with different dose schedules Dose Escalation (Part 1A): Participants receive milademetan in combination with 5-azacytidine…
- Trial name
- NCT02319369
- Testing
- Milademetan, AZA
- Where
- 5 sites in United States
- Volunteers
- 74 people
- Sponsor
- Daiichi Sankyo
Friedreich Ataxia
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
The purpose of this study is to evaluate the efficacy of TAK-831 versus placebo on upper extremity (arm and hands) motor function and manual dexterity.
- Trial name
- NCT03214588
- Testing
- TAK-831
- Where
- 6 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neurocrine Biosciences
Healthy Volunteers
Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects
This study is a phase I, randomized, placebo-controlled, double-blind (sponsor unblind), three part study. The primary objective of the study is to characterize the safety, and tolerability of GSK3008356 single dose, 14 daily…
- Trial name
- NCT02742766
- Testing
- GSK3008356
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Early-stage Parkinson's Disease
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants…
- Trial name
- ORCHESTRA (NCT04658186)
- Testing
- UCB0599
- Where
- 115 sites in United States, Canada and 7 more
- Volunteers
- 496 people
- Sponsor
- UCB Biopharma SRL
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Tuberculosis, Multidrug-Resistant
A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
A phase 2, multicenter, uncontrolled, open-label trial in participants with Multi-drug Resistant Tuberculosis (MDR-TB). Only participants who completed Trial 242-07-204 (NCT00685360) were eligible.
- Trial name
- NCT02573350
- Testing
- Delamanid, OBR
- Where
- 8 sites in China, Estonia and 4 more
- Volunteers
- 213 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Lymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered brigatinib, including: the maximum tolerated dose (MTD), dose limiting toxicities…
- Trial name
- NCT01449461
- Testing
- Brigatinib
- Volunteers
- 137 people
- Sponsor
- Ariad Pharmaceuticals
Pain, Diabetic Neuropathy
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.
- Trial name
- NCT00857623
- Testing
- AZD2066
- Where
- 19 sites in United States
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Advanced Renal Cell Carcinoma
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma…
- Trial name
- NCT03229083
- Testing
- Carevive software
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Rochester
Head and Neck Cancer
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352105
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David Adelstein
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.